Opus Genetics, Inc. Accounts Payable and Accrued Liabilities
Opus Genetics, Inc. (IRD) had Accounts Payable and Accrued Liabilities of $2.26 million as of 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2020-10-29
- 2020-09-30: Accounts Payable and Accrued Liabilities $2.26M.
- 2020-06-30: Accounts Payable and Accrued Liabilities $2.19M.
- 2020-03-31: Accounts Payable and Accrued Liabilities $1.24M.
- 2019-12-31: Accounts Payable and Accrued Liabilities $1.27M.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2020-09-30 | $2.26M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.19M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $1.24M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.27M 10-Q · filed 2020-10-29 |
| 2019-09-30 | $1.37M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.92M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.25M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $3.15M 10-K · filed 2020-02-21 |
| 2018-09-30 | $3.33M 10-Q · filed 2018-11-02 |
| 2018-06-30 | $3.38M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $3.05M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $3.23M 10-K · filed 2019-03-07 |
| 2017-09-30 | $2.34M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $1.92M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $1.72M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $1.88M 10-K · filed 2018-03-09 |
| 2016-09-30 | $1.79M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $1.79M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $3.28M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $2.66M 10-K · filed 2017-02-24 |
| 2015-09-30 | $3.24M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $3.17M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $2.75M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $2.46M 10-K · filed 2016-03-14 |
| 2014-09-30 | $1.73M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $1.54M 10-Q · filed 2014-08-13 |
| 2014-03-31 | $878.50K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $933.76K 10-K · filed 2015-03-16 |
| 2013-09-30 | $750.24K 10-Q · filed 2013-11-13 |
| 2013-06-30 | $620.07K 10-Q · filed 2013-08-12 |
| 2013-03-31 | $976.17K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $851.84K 10-K · filed 2014-03-21 |
| 2012-09-30 | $871.51K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $890.97K 10-Q · filed 2012-08-08 |
| 2011-12-31 | $1.19M 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |